1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Transmission, Human Population, and Pathogenicity: the Ebola Case in Point

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Rafael Delgado1, Fernando Simón2
  • Editors: Fernando Baquero3, Emilio Bouza4, J.A. Gutiérrez-Fuentes5, Teresa M. Coque6
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Microbiology and Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain; 2: Center for Health Alerts and Emergencies Coordination, Ministry of Health and CIBERESP, Madrid, Spain; 3: Hospital Ramón y Cajal (IRYCIS), Madrid, Spain; 4: Hospital Ramón y Cajal (IRYCIS), Madrid, Spain; 5: Complutensis University, Madrid, Spain; 6: Hospital Ramón y Cajal (IRYCIS), Madrid, Spain
  • Source: microbiolspec March 2018 vol. 6 no. 2 doi:10.1128/microbiolspec.MTBP-0003-2016
  • Received 18 August 2016 Accepted 10 March 2017 Published 22 March 2018
  • Rafael Delgado, rafael.delgado@salud.madrid.org
image of Transmission, Human Population, and Pathogenicity: the Ebola Case in Point
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Transmission, Human Population, and Pathogenicity: the Ebola Case in Point, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/6/2/MTBP-0003-2016-1.gif /docserver/preview/fulltext/microbiolspec/6/2/MTBP-0003-2016-2.gif
  • Abstract:

    The 2013–2016 Ebola outbreak in West Africa has been the largest ever of a known disease in a new context that produced an unprecedented impact and is changing the international approach to responding to public health emergencies. The unprecedented scale of the outbreak, the use of advanced technology for detecting and characterizing the infectious agent, along with the opportunity to treat patients in modern facilities have greatly increased our knowledge of the disease and its transmission. Also, for the first time, an important international effort has been deployed to control the spread of the epidemic by providing care to patients and by adopting basic measures of public health control. Apart from supportive treatment and intensive therapy with fluids and electrolytes, no new compounds have been proved to be clinically effective to treat Ebola virus disease; however, a specific vaccine has shown significant protection in clinical trials in Guinea, opening an expectation for controlling future outbreaks.

  • Keywords: filovirus; transmission; Ebola virus; R0; Ebola virus disease; hemorrhagic fever; vaccines; reproductive number

  • Citation: Delgado R, Simón F. 2018. Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. Microbiol Spectrum 6(2):MTBP-0003-2016. doi:10.1128/microbiolspec.MTBP-0003-2016.

References

1. Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST. 2014. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol 159:1229–1237. [PubMed]
2. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB. 2010. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155:2083–2103. http://dx.doi.org/10.1007/s00705-010-0814-x. [PubMed]
3. Johnson KM, Lange JV, Webb PA, Murphy FA. 1977. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1:569–571. http://dx.doi.org/10.1016/S0140-6736(77)92000-1.
4. Bowen ET, Lloyd G, Harris WJ, Platt GS, Baskerville A, Vella EE. 1977. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1:571–573. http://dx.doi.org/10.1016/S0140-6736(77)92001-3.
5. Ahmad Z, Din NU, Ahmad A, Imran S, Pervez S, Ahmed R, Kayani N. 2015. Rhabdomyosarcoma—an epidemiological and histopathologic study of 277 cases from a major tertiary care center in Karachi, Pakistan. Asian Pac J Cancer Prev 16:757–760. http://dx.doi.org/10.7314/APJCP.2015.16.2.757. [PubMed]
6. Martini GA. 1973. Marburg virus disease. Postgrad Med J 49:542–546. http://dx.doi.org/10.1136/pgmj.49.574.542. [PubMed]
7. Slenczka W, Klenk HD. 2007. Forty years of Marburg virus. J Infect Dis 196(Suppl 2):S131–S135. http://dx.doi.org/10.1086/520551. [PubMed]
8. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, Rollin PE, Towner JS, Shieh WJ, Batten B, Sealy TK, Carrillo C, Moran KE, Bracht AJ, Mayr GA, Sirios-Cruz M, Catbagan DP, Lautner EA, Ksiazek TG, White WR, McIntosh MT. 2009. Discovery of swine as a host for the Reston ebolavirus. Science 325:204–206. http://dx.doi.org/10.1126/science.1172705. [PubMed]
9. Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, Fulhorst CF, Rollin PE, Calaor AB, Manalo DL, Roces MC, Dayrit MM, Peters CJ. 1999. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 179(Suppl 1):S115–S119. http://dx.doi.org/10.1086/514314. [PubMed]
10. Feldmann H, Geisbert TW, Jahrling PB, Klenk HD, Netesov SV, Peters CJ, Sanchez A, Swanepoel R, Volchkov V. 2005. Family Filoviridae. Elsevier/Academic Press, San Diego, CA.
11. Feldmann H, Klenk HD, Sanchez A. 1993. Molecular biology and evolution of filoviruses. Arch Virol Suppl 7:81–100. http://dx.doi.org/10.1007/978-3-7091-9300-6_8. [PubMed]
12. Peters CJ, Sanchez A, Rollin PE, Ksiazek TG, Murphy GA. 1996. Filoviridae: Marburg and Ebola Viruses, vol 1. Lippincott-Raven Press, Philadelphia, PA.
13. Pringle CR. 1998. Virus taxonomy—San Diego 1998. Arch Virol 143:1449–1459. http://dx.doi.org/10.1007/s007050050389. [PubMed]
14. Bukreyev AA, Chandran K, Dolnik O, Dye JM, Ebihara H, Leroy EM, Mühlberger E, Netesov SV, Patterson JL, Paweska JT, Saphire EO, Smither SJ, Takada A, Towner JS, Volchkov VE, Warren TK, Kuhn JH. 2014. Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol 159:821–830. http://dx.doi.org/10.1007/s00705-013-1846-9. [PubMed]
15. Rollin PE, Williams RJ, Bressler DS, Pearson S, Cottingham M, Pucak G, Sanchez A, Trappier SG, Peters RL, Greer PW, Zaki S, Demarcus T, Hendricks K, Kelley M, Simpson D, Geisbert TW, Jahrling PB, Peters CJ, Ksiazek TG. 1999. Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States. J Infect Dis 179(Suppl 1):S108–S114. http://dx.doi.org/10.1086/514303. [PubMed]
16. Maruyama J, Miyamoto H, Kajihara M, Ogawa H, Maeda K, Sakoda Y, Yoshida R, Takada A. 2013. Characterization of the envelope glycoprotein of a novel filovirus, Lloviu virus. J Virol 88:99–109. http://dx.doi.org/10.1128/JVI.02265-13. [PubMed]
17. Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martínez M, Herrera JE, Pizarro M, Hutchison SK, Echevarría JE, Lipkin WI, Tenorio A. 2011. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog 7:e1002304. http://dx.doi.org/10.1371/journal.ppat.1002304. [PubMed]
18. Bogoch II, Creatore MI, Cetron MS, Brownstein JS, Pesik N, Miniota J, Tam T, Hu W, Nicolucci A, Ahmed S, Yoon JW, Berry I, Hay S, Anema A, Tatem AJ, MacFadden D, German M, Khan K. 2014. Assessment of the potential for international dissemination of Ebola virus via commercial air travel during the 2014 west African outbreak. Lancet 385:29–35. http://dx.doi.org/10.1016/s0140-6736(14)61828-6.
19. Briand S, Bertherat E, Cox P, Formenty P, Kieny MP, Myhre JK, Roth C, Shindo N, Dye C. 2014. The international Ebola emergency. N Engl J Med 371:1180–1183. [PubMed]
20. Groseth A, Feldmann H, Strong JE. 2007. The ecology of Ebola virus. Trends Microbiol 15:408–416. http://dx.doi.org/10.1016/j.tim.2007.08.001. [PubMed]
21. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska JT, Gonzalez JP, Swanepoel R. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438:575–576. http://dx.doi.org/10.1038/438575a. [PubMed]
22. Marí Saéz A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, Kühl HS, Kaba M, Regnaut S, Merkel K, Sachse A, Thiesen U, Villányi L, Boesch C, Dabrowski PW, Radonić A, Nitsche A, Leendertz SA, Petterson S, Becker S, Krähling V, Couacy-Hymann E, Akoua-Koffi C, Weber N, Schaade L, Fahr J, Borchert M, Gogarten JF, Calvignac-Spencer S, Leendertz FH. 2014. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med 7:17–23. http://dx.doi.org/10.15252/emmm.201404792. [PubMed]
23. Leroy EM, Rouquet P, Formenty P, Souquière S, Kilbourne A, Froment JM, Bermejo M, Smit S, Karesh W, Swanepoel R, Zaki SR, Rollin PE. 2004. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303:387–390. http://dx.doi.org/10.1126/science.1092528. [PubMed]
24. Walsh PD, Abernethy KA, Bermejo M, Beyers R, De Wachter P, Akou ME, Huijbregts B, Mambounga DI, Toham AK, Kilbourn AM, Lahm SA, Latour S, Maisels F, Mbina C, Mihindou Y, Obiang SN, Effa EN, Starkey MP, Telfer P, Thibault M, Tutin CE, White LJ, Wilkie DS. 2003. Catastrophic ape decline in western equatorial Africa. Nature 422:611–614. http://dx.doi.org/10.1038/nature01566. [PubMed]
25. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371:1418–1425. http://dx.doi.org/10.1056/NEJMoa1404505. [PubMed]
26. Kuhn JH, Andersen KG, Baize S, Bào Y, Bavari S, Berthet N, Blinkova O, Brister JR, Clawson AN, Fair J, Gabriel M, Garry RF, Gire SK, Goba A, Gonzalez JP, Günther S, Happi CT, Jahrling PB, Kapetshi J, Kobinger G, Kugelman JR, Leroy EM, Maganga GD, Mbala PK, Moses LM, Muyembe-Tamfum JJ, N’Faly M, Nichol ST, Omilabu SA, Palacios G, Park DJ, Paweska JT, Radoshitzky SR, Rossi CA, Sabeti PC, Schieffelin JS, Schoepp RJ, Sealfon R, Swanepoel R, Towner JS, Wada J, Wauquier N, Yozwiak NL, Formenty P. 2014. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses 6:4760–4799. http://dx.doi.org/10.3390/v6114760. [PubMed]
27. Hoenen T, Groseth A, Feldmann F, Marzi A, Ebihara H, Kobinger G, Günther S, Feldmann H. 2014. Complete genome sequences of three Ebola virus isolates from the 2014 outbreak in West Africa. Genome Announc 2:e01331-14. http://dx.doi.org/10.1128/genomeA.01331-14. [PubMed]
28. de La Vega MA, Stein D, Kobinger GP. 2015. Ebolavirus evolution: past and present. PLoS Pathog 11:e1005221. http://dx.doi.org/10.1371/journal.ppat.1005221. [PubMed]
29. Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. 1995. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345:1271–1274. http://dx.doi.org/10.1016/S0140-6736(95)90925-7.
30. Marzi A, Feldmann F, Hanley PW, Scott DP, Günther S, Feldmann H. 2015. Delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain. Emerg Infect Dis 21:1777–1783. http://dx.doi.org/10.3201/eid2110.150259. [PubMed]
31. Park DJ, Dudas G, Wohl S, Goba A, Whitmer SL, Andersen KG, Sealfon RS, Ladner JT, Kugelman JR, Matranga CB, Winnicki SM, Qu J, Gire SK, Gladden-Young A, Jalloh S, Nosamiefan D, Yozwiak NL, Moses LM, Jiang PP, Lin AE, Schaffner SF, Bird B, Towner J, Mamoh M, Gbakie M, Kanneh L, Kargbo D, Massally JL, Kamara FK, Konuwa E, Sellu J, Jalloh AA, Mustapha I, Foday M, Yillah M, Erickson BR, Sealy T, Blau D, Paddock C, Brault A, Amman B, Basile J, Bearden S, Belser J, Bergeron E, Campbell S, Chakrabarti A, Dodd K, Flint M, Gibbons A, Goodman C, Klena J, McMullan L, Morgan L, Russell B, Salzer J, Sanchez A, Wang D, Jungreis I, Tomkins-Tinch C, Kislyuk A, Lin MF, Chapman S, MacInnis B, Matthews A, Bochicchio J, Hensley LE, Kuhn JH, Nusbaum C, Schieffelin JS, Birren BW, Forget M, Nichol ST, Palacios GF, Ndiaye D, Happi C, Gevao SM, Vandi MA, Kargbo B, Holmes EC, Bedford T, Gnirke A, Ströher U, Rambaut A, Garry RF, Sabeti PC. 2015. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell 161:1516–1526. http://dx.doi.org/10.1016/j.cell.2015.06.007. [PubMed]
32. Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R. 2016. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Res 213:224–229. http://dx.doi.org/10.1016/j.virusres.2015.12.019. [PubMed]
33. Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H. 2015. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349:739–742. http://dx.doi.org/10.1126/science.aab3920. [PubMed]
34. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen J-A. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–866. http://dx.doi.org/10.1016/S0140-6736(15)61117-5.
35. Deen GF, Knust B, Broutet N, Sesay FR, Formenty P, Ross C, Thorson AE, Massaquoi TA, Marrinan JE, Ervin E, Jambai A, McDonald SL, Bernstein K, Wurie AH, Dumbuya MS, Abad N, Idriss B, Wi T, Bennett SD, Davies T, Ebrahim FK, Meites E, Naidoo D, Smith S, Banerjee A, Erickson BR, Brault A, Durski KN, Winter J, Sealy T, Nichol ST, Lamunu M, Ströher U, Morgan O, Sahr F. 2015. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med http://dx.doi.org/10.1056/NEJMoa1511410.
36. Mate SE, Kugelman JR, Nyenswah TG, Ladner JT, Wiley MR, Cordier-Lassalle T, Christie A, Schroth GP, Gross SM, Davies-Wayne GJ, Shinde SA, Murugan R, Sieh SB, Badio M, Fakoli L, Taweh F, de Wit E, van Doremalen N, Munster VJ, Pettitt J, Prieto K, Humrighouse BW, Ströher U, DiClaro JW, Hensley LE, Schoepp RJ, Safronetz D, Fair J, Kuhn JH, Blackley DJ, Laney AS, Williams DE, Lo T, Gasasira A, Nichol ST, Formenty P, Kateh FN, De Cock KM, Bolay F, Sanchez-Lockhart M, Palacios G. 2015. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 373:2448–2454. http://dx.doi.org/10.1056/NEJMoa1509773. [PubMed]
37. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 372:2423–2427. http://dx.doi.org/10.1056/NEJMoa1500306. [PubMed]
38. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, Gifford RJ, Hopkins S, Hughes J, Jabeen F, Johannessen I, Karageorgopoulos D, Lackenby A, Lester R, Liu RS, MacConnachie A, Mahungu T, Martin D, Marshall N, Mepham S, Orton R, Palmarini M, Patel M, Perry C, Peters SE, Porter D, Ritchie D, Ritchie ND, Seaton RA, Sreenu VB, Templeton K, Warren S, Wilkie GS, Zambon M, Gopal R, Thomson EC. 2016. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388:498–503. http://dx.doi.org/10.1016/S0140-6736(16)30386-5.
39. Alvarez CP, Lasala F, Carrillo J, Muñiz O, Corbí AL, Delgado R. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76:6841–6844. http://dx.doi.org/10.1128/JVI.76.13.6841-6844.2002. [PubMed]
40. Dominguez-Soto A, Aragoneses-Fenoll L, Martin-Gayo E, Martinez-Prats L, Colmenares M, Naranjo-Gomez M, Borras FE, Munoz P, Zubiaur M, Toribio ML, Delgado R, Corbi AL. 2007. The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells. Blood 109:5337–5345. http://dx.doi.org/10.1182/blood-2006-09-048058. [PubMed]
41. Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF. 2016. Differential regulation of interferon responses by Ebola and Marburg virus VP35 proteins. Cell Rep 14:1632–1640. http://dx.doi.org/10.1016/j.celrep.2016.01.049. [PubMed]
42. Xu W, Edwards MR, Borek DM, Feagins AR, Mittal A, Alinger JB, Berry KN, Yen B, Hamilton J, Brett TJ, Pappu RV, Leung DW, Basler CF, Amarasinghe GK. 2014. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 16:187–200. http://dx.doi.org/10.1016/j.chom.2014.07.008. [PubMed]
43. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6:886–889. http://dx.doi.org/10.1038/78645. [PubMed]
44. Walsh PD, Biek R, Real LA. 2005. Wave-like spread of Ebola Zaire. PLoS Biol 3:e371. http://dx.doi.org/10.1371/journal.pbio.0030371. [PubMed]
45. Pinzon JE, Wilson JM, Tucker CJ, Arthur R, Jahrling PB, Formenty P. 2004. Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg 71:664–674. [PubMed]
46. Gonzalez JP, Pourrut X, Leroy E. 2007. Ebolavirus and other filoviruses. Curr Top Microbiol Immunol 315:363–387. http://dx.doi.org/10.1007/978-3-540-70962-6_15. [PubMed]
47. Anonymous. 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56:247–270. [PubMed]
48. Anonymous. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56:271–293. [PubMed]
49. Anderson RM, May RM. 1991. Infectious Diseases of Humans. Oxford University Press, Oxford, United Kingdom.
50. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H, ESEN Project. European Sero-epidemiology Network. 2000. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect 125:635–650. http://dx.doi.org/10.1017/S0950268800004672. [PubMed]
51. Chowell G, Hengartner NW, Castillo-Chavez C, Fenimore PW, Hyman JM. 2004. The basic reproductive number of Ebola and the effects of public health measures: the cases of Congo and Uganda. J Theor Biol 229:119–126 http://dx.doi.org/10.1016/j.jtbi.2004.03.006. [PubMed]
52. Breman JG, Heymann DL, Lloyd G, McCormick JB, Miatudila M, Murphy FA, Muyembé-Tamfun JJ, Piot P, Ruppol JF, Sureau P, van der Groen G, Johnson KM. 2016. Discovery and description of Ebola Zaire virus in 1976 and relevance to the West African epidemic during 2013–2016. J Infect Dis 214(suppl 3):S93–S101. http://dx.doi.org/10.1093/infdis/jiw207. [PubMed]
53. Team WHOER, WHO Ebola Response Team. 2014. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371:1481–1495. http://dx.doi.org/10.1056/NEJMoa1411100. [PubMed]
54. Barbarossa MV, Dénes A, Kiss G, Nakata Y, Röst G, Vizi Z. 2015. Transmission dynamics and final epidemic size of Ebola virus disease outbreaks with varying interventions. PLoS One 10:e0131398. http://dx.doi.org/10.1371/journal.pone.0131398. [PubMed]
55. World Health Organization Sierra Leone: a traditional healer and a funeral. http://www.who.int/csr/disease/ebola/ebola-6-months/sierra-leone/en/. Accessed July 20, 2016.
56. Agua-Agum J, Ariyarajah A, Aylward B, Blake IM, Brennan R, Cori A, Donnelly CA, Dorigatti I, Dye C, Eckmanns T, Ferguson NM, Formenty P, Fraser C, Garcia E, Garske T, Hinsley W, Holmes D, Hugonnet S, Iyengar S, Jombart T, Krishnan R, Meijers S, Mills HL, Mohamed Y, Nedjati-Gilani G, Newton E, Nouvellet P, Pelletier L, Perkins D, Riley S, Sagrado M, Schnitzler J, Schumacher D, Shah A, Van Kerkhove MD, Varsaneux O, Wijekoon Kannangarage N, WHO Ebola Response Team. 2015. West African Ebola epidemic after one year—slowing but not yet under control. N Engl J Med 372:584–587. http://dx.doi.org/10.1056/NEJMc1414992. [PubMed]
57. Peters CJ, LeDuc JW. 1999. An introduction to Ebola: the virus and the disease. J Infect Dis 179(Suppl 1):ix–xvi. http://dx.doi.org/10.1086/514322. [PubMed]
58. Grinnell M, Dixon MG, Patton M, Fitter D, Bilivogui P, Johnson C, Dotson E, Diallo B, Rodier G, Raghunathan P. 2015. Ebola virus disease in health care workers—Guinea, 2014. MMWR Morb Mortal Wkly Rep 64:1083–1087. http://dx.doi.org/10.15585/mmwr.mm6438a6. [PubMed]
59. Evans DK, Goldstein M, Popova A. 2015. Health-care worker mortality and the legacy of the Ebola epidemic. Lancet Glob Health 3:e439–e440. http://dx.doi.org/10.1016/S2214-109X(15)00065-0.
60. Uyeki TM, Mehta AK, Davey RT, Jr, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, Hoepelman AI, Gutman J, Working Group of the U.S.-European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. 2016. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 374:636–646. http://dx.doi.org/10.1056/NEJMoa1504874. [PubMed]
61. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, Sealfon RS, Kanneh L, Moigboi A, Momoh M, Fullah M, Moses LM, Brown BL, Andersen KG, Winnicki S, Schaffner SF, Park DJ, Yozwiak NL, Jiang PP, Kargbo D, Jalloh S, Fonnie M, Sinnah V, French I, Kovoma A, Kamara FK, Tucker V, Konuwa E, Sellu J, Mustapha I, Foday M, Yillah M, Kanneh F, Saffa S, Massally JL, Boisen ML, Branco LM, Vandi MA, Grant DS, Happi C, Gevao SM, Fletcher TE, Fowler RA, Bausch DG, Sabeti PC, Khan SH, Garry RF, KGH Lassa Fever Program, Viral Hemorrhagic Fever Consortium, WHO Clinical Response Team. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371:2092–2100. [PubMed]
62. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, Shindo N, Fischer WA, II, Lamontagne F, Saliou SM, Bausch DG, Moumié B, Jagatic T, Sprecher A, Lawler JV, Mayet T, Jacquerioz FA, Méndez Baggi MF, Vallenas C, Clement C, Mardel S, Faye O, Faye O, Soropogui B, Magassouba N, Koivogui L, Pinto R, Fowler RA. 2015. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372:40–47. http://dx.doi.org/10.1056/NEJMoa1411249. [PubMed]
63. Qin E, Bi J, Zhao M, Wang Y, Guo T, Yan T, Li Z, Sun J, Zhang J, Chen S, Wu Y, Li J, Zhong Y. 2015. Clinical features of patients with Ebola virus disease in Sierra Leone. Clin Infect Dis 61:491–495. http://dx.doi.org/10.1093/cid/civ319. [PubMed]
64. Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, Bore JA, Koundouno R, Dudas G, Mikhail A, Ouédraogo N, Afrough B, Bah A, Baum JH, Becker-Ziaja B, Boettcher JP, Cabeza-Cabrerizo M, Camino-Sánchez Á, Carter LL, Doerrbecker J, Enkirch T, García-Dorival I, Hetzelt N, Hinzmann J, Holm T, Kafetzopoulou LE, Koropogui M, Kosgey A, Kuisma E, Logue CH, Mazzarelli A, Meisel S, Mertens M, Michel J, Ngabo D, Nitzsche K, Pallasch E, Patrono LV, Portmann J, Repits JG, Rickett NY, Sachse A, Singethan K, Vitoriano I, Yemanaberhan RL, Zekeng EG, Racine T, Bello A, Sall AA, Faye O, Faye O, Magassouba N, Williams CV, Amburgey V, Winona L, Davis E, Gerlach J, Washington F, Monteil V, Jourdain M, Bererd M, Camara A, Somlare H, Camara A, Gerard M, Bado G, Baillet B, Delaune D, Nebie KY, Diarra A, Savane Y, Pallawo RB, Gutierrez GJ, Milhano N, Roger I, Williams CJ, Yattara F, Lewandowski K, Taylor J, Rachwal P, Turner DJ, Pollakis G, Hiscox JA, Matthews DA, O’Shea MK, Johnston AM, Wilson D, Hutley E, Smit E, Di Caro A, Wölfel R, Stoecker K, Fleischmann E, Gabriel M, Weller SA, Koivogui L, Diallo B, Keïta S, Rambaut A, Formenty P, Günther S, Carroll MW. 2016. Real-time, portable genome sequencing for Ebola surveillance. Nature 530:228–232. http://dx.doi.org/10.1038/nature16996. [PubMed]
65. Hoenen T, Groseth A, Rosenke K, Fischer RJ, Hoenen A, Judson SD, Martellaro C, Falzarano D, Marzi A, Squires RB, Wollenberg KR, de Wit E, Prescott J, Safronetz D, van Doremalen N, Bushmaker T, Feldmann F, McNally K, Bolay FK, Fields B, Sealy T, Rayfield M, Nichol ST, Zoon KC, Massaquoi M, Munster VJ, Feldmann H. 2016. Nanopore sequencing as a rapidly deployable Ebola outbreak tool. Emerg Infect Dis 22:331–334. http://dx.doi.org/10.3201/eid2202.151796. [PubMed]
66. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fernandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman EN, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CE, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S. 2015. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature 524:97–101. http://dx.doi.org/10.1038/nature14594. [PubMed]
67. Hoenen T, Safronetz D, Groseth A, Wollenberg KR, Koita OA, Diarra B, Fall IS, Haidara FC, Diallo F, Sanogo M, Sarro YS, Kone A, Togo AC, Traore A, Kodio M, Dosseh A, Rosenke K, de Wit E, Feldmann F, Ebihara H, Munster VJ, Zoon KC, Feldmann H, Sow S. 2015. Virology. Mutation rate and genotype variation of Ebola virus from Mali case sequences. Science 348:117–119. http://dx.doi.org/10.1126/science.aaa5646. [PubMed]
68. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S, Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S, Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang PP, Nekoui M, Colubri A, Coomber MR, Fonnie M, Moigboi A, Gbakie M, Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A, Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W, Massally JL, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S, Birren BW, Grant DS, Scheiffelin JS, Lander ES, Happi C, Gevao SM, Gnirke A, Rambaut A, Garry RF, Khan SH, Sabeti PC. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345:1369–1372. http://dx.doi.org/10.1126/science.1259657. [PubMed]
69. Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF. 2015. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep 12:2111–2120. http://dx.doi.org/10.1016/j.celrep.2015.08.038. [PubMed]
70. Kugelman JR, Wiley MR, Mate S, Ladner JT, Beitzel B, Fakoli L, Taweh F, Prieto K, Diclaro JW, Minogue T, Schoepp RJ, Schaecher KE, Pettitt J, Bateman S, Fair J, Kuhn JH, Hensley L, Park DJ, Sabeti PC, Sanchez-Lockhart M, Bolay FK, Palacios G, US Army Medical Research Institute of Infectious Diseases, National Institutes of Health, Integrated Research Facility–Frederick Ebola Response Team 2014-2015. 2015. Monitoring of Ebola virus Makona evolution through establishment of advanced genomic capability in Liberia. Emerg Infect Dis 21:1135–1143. http://dx.doi.org/10.3201/eid2107.150522. [PubMed]
71. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53. [PubMed]
72. Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375:1896–1905. http://dx.doi.org/10.1016/S0140-6736(10)60357-1.
73. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21. http://dx.doi.org/10.1016/j.antiviral.2014.02.014. [PubMed]
74. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen SS, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–385. http://dx.doi.org/10.1038/nature17180. [PubMed]
75. Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D’Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D, JIKI Study Group. 2016. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13:e1001967. http://dx.doi.org/10.1371/journal.pmed.1001967. [PubMed]
76. Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B, Massaquoi T, Gandi R, Joseph S, Osman HK, Brooks TJ, Simpson AJ, Goodfellow I, Thorne L, Arias A, Merson L, Castle L, Howell-Jones R, Pardinaz-Solis R, Hope-Gill B, Ferri M, Grove J, Kowalski M, Stepniewska K, Lang T, Whitehead J, Olliaro P, Samai M, Horby PW, RAPIDE-TKM trial team. 2016. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 13:e1001997. http://dx.doi.org/10.1371/journal.pmed.1001997. [PubMed]
77. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N, Ebola-Tx Consortium. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374:33–42. http://dx.doi.org/10.1056/NEJMoa1511812. [PubMed]
78. Lamontagne F, Clément C, Fletcher T, Jacob ST, Fischer WA, II, Fowler RA. 2014. Doing today’s work superbly well—treating Ebola with current tools. N Engl J Med 371:1565–1566. http://dx.doi.org/10.1056/NEJMp1411310. [PubMed]
79. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, Foulds KE, Cheng C, Wang L, Donaldson MM, Colloca S, Folgori A, Roederer M, Nabel GJ, Mascola J, Nicosia A, Cortese R, Koup RA, Sullivan NJ. 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20:1126–1129. [PubMed]
80. Marzi A, Feldmann H, Geisbert TW, Falzarano D. 2011. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef S1:2157-2526-S1-004.
81. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, Gordon IJ, Plummer SA, Holman LA, Hendel CS, Yamshchikov G, Roman F, Nicosia A, Colloca S, Cortese R, Bailer RT, Schwartz RM, Roederer M, Mascola JR, Koup RA, Sullivan NJ, Graham, B. S. 2017. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med 376(10):928–938. http://dx.doi.org/10.1056/NEJMoa1410863. [PubMed]
82. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. 2016. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374:1647–1660. http://dx.doi.org/10.1056/NEJMoa1502924. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.MTBP-0003-2016
2018-03-22
2018-04-22

Abstract:

The 2013–2016 Ebola outbreak in West Africa has been the largest ever of a known disease in a new context that produced an unprecedented impact and is changing the international approach to responding to public health emergencies. The unprecedented scale of the outbreak, the use of advanced technology for detecting and characterizing the infectious agent, along with the opportunity to treat patients in modern facilities have greatly increased our knowledge of the disease and its transmission. Also, for the first time, an important international effort has been deployed to control the spread of the epidemic by providing care to patients and by adopting basic measures of public health control. Apart from supportive treatment and intensive therapy with fluids and electrolytes, no new compounds have been proved to be clinically effective to treat Ebola virus disease; however, a specific vaccine has shown significant protection in clinical trials in Guinea, opening an expectation for controlling future outbreaks.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Tables

Generic image for table
TABLE 1

Cases and deaths among health care professionals, Ebola outbreak in West Africa, 2014–2016

Source: microbiolspec March 2018 vol. 6 no. 2 doi:10.1128/microbiolspec.MTBP-0003-2016

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error